Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Littlebits who wrote (11264)	5/14/2012 6:27:56 PM
From: LT2011	Read Replies (3) \| Respond to of 13111

Based on the 8-K that was filed today Dr Wachter is no longer the VP of Pharmaceuticals. Does anybody know if this would impact his ability to receive stock options? Is the Chief Technology Office considered an executive position within PVCT? Why the name change? Couldn't he have handled his new assignment with the same VP title? ++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++ Effective May 14, 2012, Dr. Wachter has been named the Company’s Chief Technology Officer, a new position, which replaces Dr. Wachter’s current role as Executive Vice President—Pharmaceuticals Dr. Wachter, age 49, has been with Provectus since 2002, and has served as Executive Vice President-Pharmaceuticals and a Director of the Company since that time. As Chief Technology Officer of Provectus, Dr. Wachter’s new position will focus on leading drug development of both PV-10 and PH-10 as well as the intellectual property (“IP”) protection of its investigational therapeutic products. With Phase 2 clinical trials for both PV-10 and PH-10 completed, Dr. Wachter will continue spearheading the Company’s regulatory efforts, including clinical, nonclinical and manufacturing programs necessary for FDA and international approval and commercialization. Dr. Wachter holds 27 U.S. patents, was a co-founder of Photogen Technologies, where he held several senior management positions, and was also a senior research staff member at the Oak Ridge National Laboratory. He holds a Ph.D. in chemistry from the University of Wisconsin, Madison and a B.S. degree in chemistry from Indiana University-Bloomington.